Clinical Trials Logo

Clinical Trial Summary

Deep transcranial magnetic stimulation (TMS) is currently being evaluated as a treatment option in major depression. It has been shown to be a safe procedure . Deep transcranial magnetic stimulation coils are designed to maximize the electrical field deep in the brain by the summation of separate fields projected into the skull from several points around its periphery. The device is planned to minimize the accumulation of electrical charge on the surface of the brain. Such accumulation can give rise to an electrostatic field that might reduce the magnitude of the induced electric field both at the surface and inside, thus reducing the depth penetration of the induced electric field . Deep transcranial magnetic stimulation could be more effective than repetitive transcranial magnetic stimulation due to its deeper penetration into brain tissues . The deeper penetration should produce greater action on nerve fibers connecting the prefrontal cortex to the limbic system.

The ability of high-frequency repetitive transcranial magnetic stimulation (rTMS) to alter dopaminergic neurotransmission in subcortical structures could explain recent reports, which suggest that it has the potential to reduce smoking and nicotine craving. Ecihhammer et al demonstrated a reduction in the number of cigarettes smoked and in the desire to smoke after a single rTMS treatment (Eichhammer et al., 2003). In addition, Johan et al in a cross-over, double-blind, placebo-controlled study demonstrated a reduction in cigarette consumption and desire to smoke after a single repetitive transcranial magnetic stimulation treatment (Johann et al., 2003). Recently, the investigators have finished a complete study on nicotine addiction using repetitive transcranial magnetic stimulation for 10 consecutive days. They have found that 10 days of rTMS reduced significantly better from placebo the number of cigarettes smoked, nicotine dependence and craving (Amiaz et al 2007, in preparation). Interestingly, some of the effects were stronger in the sub-group of patients that were presented with smoking-related pictures immediately prior to stimulation onset. Although, these results are interesting and exciting, they have two important caveats. First, only about 50%-60% of the smokers responded to the repetitive transcranial magnetic stimulation treatment. Second, among those responded to the treatment, only 10% had quit totally from smoking. Therefore, the potential therapeutic benefit of this treatment is limited. The investigators' hypothesis is that deep transcranial magnetic stimulation may be more efficient in smoking cessation due to it's deeper penetration and therefore it's capability to stimulate deeper fibers of the dopamine-reward-activating system.


Clinical Trial Description

Research Plan

I. PARTICIPANTS Male and female cigarette smokers who suffer from COPD. From the general population aged 21-70 who wishes to quit smoking and failed to respond to previous anti-smoking treatment. They will be recruited by advertisements in the newspapers and specific websites. The number of participants in each sub-group (as described in the table below) will be 15-17. The investigators will recruit 90-102 subjects over two years.

II. SCREENING PROCEDURE

Before stimulation procedures onset, participants will undergo a clinical interview. All subject candidates will give written informed consent to take part in the study. Thereafter, they will be tested for their baseline pretreatment level of nicotine addiction in a screening meeting. This includes a report on the level of consumption (number of cigarettes smoked per day and overall duration in years) and a visual analog scale (VAS, see below for details). In addition, a urine sample for cotinine levels (nicotine metabolite) will be obtained in order to objectively measure levels of nicotine. In addition, several self-administered questionnaires will be given to the subjects in order to measure their baseline craving and nicotine dependence:

1. Fagerstrom Test of Nicotine Dependence (FTND) (Heatherton et al., 1991). (Appendix no.1a)

2. Tobacco Craving Questionnaire (TCQ) (Heishman et al., 2003). (Appendix no.1b)

3. Full demographic questionnaire about medical condition and smoking habits. (Appendix no.1c)

III. MEASURES

All subjects will undergo various measurements on several visits, as described in table 1-3, for nicotine consumption, craving and dependence during the rTMS treatment visits:

1. VAS: Visual Analogue Scale, on which the subject marks his/her subjective craving on a 10-cm-long scale in response to the following question: "How much do you crave a joint/bong right now?" This "desire to smoke rating" has been shown to be sensitive to assess self-reported levels of craving in nicotine smoking (Schuh and Stitzer, 1995; King and Meyer, 2000).

2. Short TCQ: Tobacco Craving Questionnaire, the short version of the TCQ, which has 12 questions that can be divided into four categories: emotionality, expectancy, compulsivity and purposefulness.

3. FTND: Fagerstrom Test of Nicotine Dependence. Measures the level of nicotine dependence (Dijkstra and Tromp, 2002).

4. Self-report of the number of cigarettes smoked on the previous day.

5. Urine sample.

6. BR: desire to smoke and effect on hunger.

7. Spatial span memory test - in order to evaluate the effect of deep rTMS on spatial memory. This test will be conducted in the screening interview and after 10 days of rTMS treatment.

IV. PRESENTATION OF PHOTOGRAPHS

It has recently been demonstrated that in nicotine-deprived smokers, reward and attention circuits are reactivated by mere exposure to smoking-related images, in contrast with neutral images (Due et al., 2002). In our experiment, prior to stimulation onset 14 'neutral' or 'nicotine-related' colored photographs will be presented on a computer screen to the participants while there are seated. The 'nicotine-related' photographs will be composed from smoking-related scenes, such as lighting up a cigarette, smoking puffs etc. 'Neutral' photos will consist of matched pictures without any nicotine related content (e.g. inanimate objects, hands, faces etc.). As the investigators have previously shown with the figure-8 coil experiment, there was a stronger effect of the rTMS treatment in subjects exposed to the nicotine photographs. The investigators propose that presentation of the nicotine photographs causes the nicotine-related memories to become activated and therefore, labile for interference, as previously has been shown (Dudai, 2004 ).

V. EXPERIMENTAL PROCEDURES

After screening of the participants while taking into account the inclusion and exclusion criteria (described above), they will be divided into experimental groups having similar levels of nicotine addiction and demographic background. At selected time afterwards, participants will be introduced to the TMS treatment protocol. They will be asked to refrain from smoking nicotine for two hours prior to attending the daily treatment session. Prior to stimulation onset, the participants will be presented with 'nicotine' photographs. Immediately after the offset of the photographs presentation (while memory is reactivated) the participants will be applied with real or sham rTMS stimulation. The stimulation site will be the PFC using the H-ADD coil.

Time Table:

There will be daily treatments for two weeks accompanied with assessment of the level of nicotine addiction on selected days using the above-mentioned tools. Thereafter, subjects will continue to have maintenance rTMS/sham stimulation treatment: 3 times a week for one week, two times a week in the forth and fifth week, once a week in the sixth and seventh week (see also table 2). After maintenance, participants will continue with follow up visits that will occur once a month for six months (see table 3). This protocol will allow evaluation of the short and long-term effects of the rTMS treatment with the possible fluctuations over time.

TMS procedure:

The investigators will use a Magstim Super Rapid stimulator, which produces a biphasic pulse, and our special customized equipment and coils for deep brain stimulation (Zangen, 2005 ). The TMS coils, which will be used in this study will be specific versions of the H-coil, depending on the region of stimulation. The H-coil versions used in this study, the H-ADD coil, have been tested in healthy volunteers and found to be safe and to induce some short-lasting (1 hour) cognitive alterations (Levkovitz et al., 2007, accepted). The theoretical considerations and design principles of the H-coils are explained in a previous study (Roth, 2002 ). In short, the H-ADD coil is designed to generate summation of the electric field in a specific brain region by locating coil elements at different locations around this region, all of which have a common current component which induce electric field in the desired direction .In addition, since a radial component has a dramatic effect on electric field magnitude and on the rate of decay of the electric field with distance, the overall length of coil elements which are nontangential to the skull should be minimized, and these elements as well as coil elements having current component in the opposite direction should be located as distant as possible from the brain region to be activated.

The H-ADD coil is placed on the scalp over the left motor cortex. The center of the coil is placed on the scalp with the handle pointing backward and laterally at a 45° angle away from the midline. Thus the current induced in the neural tissue is directed approximately perpendicular to the line of the central sulcus and therefore optimal for activating the corticospinal pathways transsynaptically (Kaneko et al., 1996). With a slightly suprathreshold stimulus intensity, the stimulating H-ADD coil is moved over the left hemisphere to determine the optimal position for eliciting MEPs of maximal amplitudes (the 'hot spot'). The optimal position of the coil is then marked relative to the 'hot spot' to ensure coil placement throughout the experiment. Resting motor threshold is determined to the nearest 1% of the maximum stimulator output and is defined as the minimal stimulus intensity required to produce MEPs of >50 µV in ≥5 of 10 consecutive trials at least 5 sec apart. The H-ADD coil is held in a stable coil holder ,which can be adjusted at different points relative to the 'hot spot' on the scalp.

Stimulation Protocols:

The investigators will use either sham or real H-ADD coils, which both produce similar noise and share a similar shape (as the investigators have been using in our study on healthy volunteers). Stimulation intensity will be 120% relative to the motor threshold in the 'hot spot'. PFC location will be determined as follows: 6 cm anterior to the motor 'hot spot' and symmetric.

High frequency stimulation will by applied in order to achieve activation of the stimulated brain area and possibly induce LTP like plasticity. The stimulation protocol will be 33 trains of 10 Hz for 3 seconds, ITI of 20 seconds. The total treatment duration will be 759 seconds with 990 pulses. . For that purpose the investigators have designed a special cooling system for our coils and used them successfully in our healthy volunteers study (Levkovitz et al., 2007, accepted). ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00951782
Study type Interventional
Source BeerYaakov Mental Health Center
Contact
Status Completed
Phase Phase 2/Phase 3
Start date October 2009
Completion date May 2013

See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy